AIM: To find better ways of treating ocular alkali burn, and to reduce the suffering of patients and social burden.

METHODS:Totally 100 patients were graded according to the degree of chemical burns to four major groups, each half were randomly divided into the control group and the treatment group. Control group underwent conventional treatment. In addition to conventional therapy, patients in each treatment group were also added a Breviscapine intravenous injection of 40mg daily. Corneal recovery time, changes in vision, degree of corneal opacity, number of corneal neovascularization and other complications were observed. Curative effects were analyzed statistically.

RESULTS: There was no significant difference in level Ⅰ group between control group and treatment group(P>0.05); There were significantly different in level Ⅱ, Ⅲ and Ⅳ group(P<0.05). Compared to the degree of corneal opacity and the number of corneal neovascularization, the treatment group was obviously better than the control group(P<0.05).

CONCLUSION: Breviscapine in the treatment of ocular alkali burns can shorten the course of treatment, reduce corneal scarring, and improve vision.